Head-to-head Comparison: OraSure Technologies (NASDAQ:OSUR) vs. Pro-Dex (NASDAQ:PDEX)

OraSure Technologies ( NASDAQ:OSUR – Get Your Free Report ) and Pro-Dex ( NASDAQ:PDEX – Get Your Free Report ) are both small-cap medical companies, but which is the superior business? We’ll compare the two companies based on their risk strength, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Rating and Earnings

This table compares OraSure Technologies and Pro-Dex’s top-line revenue, earnings per share (EPS) and valuation.

OraSure Technologies has higher revenue and earnings than Pro-Dex. OraSure Technologies is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Institutional and privileged ownership

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 3.4% of OraSure Technologies shares are held by insiders. Comparatively, 42.6% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a stock will outperform the market over the long term.

Analyst ratings

This is a summary of recent recommendations for OraSure Technologies and Pro-Dex as provided by MarketBeat.

OraSure Technologies currently has a consensus target price of $6.67, suggesting a potential upside of 51.52%. Pro-Dex has a consensus target price of $30.00, suggesting a potential upside of 5.67%. Given OraSure Technologies’ higher probable upside, equities analysts clearly believe OraSure Technologies is more favorable than Pro-Dex.

Risk and volatility

OraSure Technologies has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.38, indicating that its share price its stock is 62% less volatile than the S&P 500.

return

This table compares OraSure Technologies and Pro-Dex’s net margins, return on equity and return on assets.

Summary

OraSure Technologies beats Pro-Dex on 7 of the 13 factors compared between the two stocks.

About OraSure Technologies

(Get a free report)

OraSure Technologies, Inc., together with its subsidiaries, provides home and point-of-care diagnostic tests, specimen collection devices, and microbiome analysis and laboratory services in the United States, Europe and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, the OraQuick Ebola antigen rapid test, the OraSure oral fluid collection device used in conjunction with HIV-1 antibody screening and confirmatory tests; Interception of drug testing systems; immunological tests and reagents; and the QED saliva alcohol test. It also offers genomic products under the Orogene and ORAcollect brands for the collection of genetic material from human saliva; Colli-Pee collection devices for volumetric collection of urine samples; and microbiome analysis and laboratory testing services. In addition, the company provides microbiome products such as OMNIgene GUT for self-collection of microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and the OMNIgene GUT Dx collection device for collecting human fecal samples and stabilizing DNA from the bacterial community. In addition, it offers other diagnostic products such as immunoassays and other in vitro diagnostic tests. The Company markets its products to clinical laboratories, hospitals, clinics, community and other public health organizations, distributors, government agencies, medical practices, commercial and industrial entities, disease risk management, diagnostics, pharmaceuticals, biotechnology, nutrition, companion markets of animals and the environment. OraSure Technologies, Inc. was founded in 2000 and is headquartered in Bethlehem, Pennsylvania.

About Pro-Dex

(Get a free report)

Pro-Dex, Inc. designs, develops, manufactures and sells motorized surgical instruments for original equipment manufacturers for medical devices worldwide. The company offers autoclavable, battery-powered, electric, and multi-functional surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality and regulatory consulting services; and manufactures and sells rotary air motors for various industries. The company’s products are used in hospitals, medical engineering laboratories, scientific research facilities and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Get news and reviews for OraSure Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OraSure Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.